2-[(6-bromo-1H-benzimidazol-2-yl)methyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one | 1260544-04-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[(6-bromo-1H-benzimidazol-2-yl)methyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one
• 英文别名: 2-[(5-bromo-1H-benzimidazol-2-yl)methyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one；2-[(6-bromo-1H-benzimidazol-2-yl)methyl]-4-morpholin-4-yl-1H-pyrimidin-6-one
• CAS: 1260544-04-4
• 化学式: C₁₆H₁₆BrN₅O₂
• 分子量: 390.239
• InChiKey: MXWXREUDDBTARZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  82.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl [4-(morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]acetate 在 吡啶 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.0h， 生成 2-[(6-bromo-1H-benzimidazol-2-yl)methyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one
  参考文献：
  名称：

  NOVEL 1H-PYRIMIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS INHIBITORS OF AKT (PKB) PHOSPHORYLATION

  摘要：

  这项发明涉及公式(I)的新产品：其中Z代表—O—、—NH或Nalk；n代表0至4；R1代表Hal、羟基、烷基或烷氧基；烷基和烷氧基基团可选择性取代；R2和R3代表H、Hal或烷基，可选择性取代一个或多个卤素原子；R4代表H；这些产品在所有异构体形式和盐中作为药物，特别是作为AKT(PKB)磷酸化抑制剂。

  公开号：

  US20120172360A1

文献信息

• NOVEL 1H-PYRIMIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS INHIBITORS OF AKT (PKB) PHOSPHORYLATION
  申请人：CERTAL Victor

  公开号：US20120172360A1

  公开（公告）日：2012-07-05

  The invention relates to the novel products of formula (I): in which Z represents —O—, —NH or Nalk; n represents 0 to 4; R1 represents Hal, hydroxyl, alkyl or alkoxy; the alkyl and alkoxy radicals being optionally substituted; R2 and R3 represent H, Hal or alkyl optionally substituted with one or more halogen atoms; R4 represents H; these products being in all the isomer forms and the salts, as medicaments, in particular as inhibitors of AKT(PKB) phosphorylation.

  这项发明涉及公式(I)的新产品：其中Z代表—O—、—NH或Nalk；n代表0至4；R1代表Hal、羟基、烷基或烷氧基；烷基和烷氧基基团可选择性取代；R2和R3代表H、Hal或烷基，可选择性取代一个或多个卤素原子；R4代表H；这些产品在所有异构体形式和盐中作为药物，特别是作为AKT(PKB)磷酸化抑制剂。
• 1H-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of AKT (PKB) phosphorylation
  申请人：Certal Victor

  公开号：US08507483B2

  公开（公告）日：2013-08-13

  The invention relates to the novel products of formula (I): in which Z represents —O—, —NH or Nalk; n represents 0 to 4; R1 represents Hal, hydroxyl, alkyl or alkoxy; the alkyl and alkoxy radicals being optionally substituted; R2 and R3 represent H, Hal or alkyl optionally substituted with one or more halogen atoms; R4 represents H; these products being in all the isomer forms and the salts, as medicaments, in particular as inhibitors of AKT(PKB) phosphorylation.

  本发明涉及公式(I)的新产品： 其中，Z代表—O—，—NH或Nalk；n代表0至4；R1代表Hal、羟基、烷基或烷氧基；烷基和烷氧基基团可选地被取代；R2和R3代表H、Hal或烷基，可选地被一个或多个卤素原子取代；R4代表H。这些产品以所有异构体形式和盐的形式作为药物，特别是作为AKT（PKB）磷酸化抑制剂。
• NOUVEAUX DERIVES DE 6-MORPHOLIN-4-YL-PYRIMIDIN-4- ( 3H ) -ONE, LEUR PREPARATION PHARMACEUTIQUE COMME INHIBITEURS DE PHOS PHORYLAT I ON D ' AKT ( PKB )
  申请人：SANOFI

  公开号：EP2448932A1

  公开（公告）日：2012-05-09
• NOUVEAUX DERIVES DE 6-MORPHOLIN-4-YL-PYRIMIDIN-4-(3H)-ONE, LEUR PREPARATION PHARMACEUTIQUE COMME INHIBITEURS DE PHOSPHORYLATION D'AKT(PKB)
  申请人：SANOFI

  公开号：EP2448932B1

  公开（公告）日：2014-03-05
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.